What Happened
Eli Lilly has won a self-regulatory challenge against a telehealth seller of compounded tirzepatide, forcing the company to pull the health-benefit and "personalized" claims that carried its marketing.
On November 4, the National Advertising Division (NAD) of BBB National Programs published its decision in a challenge Lilly brought against Good Life Meds, a telehealth platform selling a compounded tirzepatide product marketed as "Tirzepatide+." NAD recommended it discontinue the challenged express claims and revise its ads so they no longer imply the product is safe and effective for those benefits or delivers significant weight-loss results.
Tirzepatide is the active ingredient in Mounjaro and Zepbound, the only FDA-approved tirzepatide medicines, both made by Lilly.
What Was Challenged
- Health benefits — that Tirzepatide+ supports healthy weight loss, provides "natural energy boosts," improves blood sugar control, and preserves lean muscle mass.
- Personalization — that the product is a "personalized medication… tailored to meet individual patient needs," "custom formulated," and "compounded for your unique needs."
Why the Evidence Fell Short
Good Life submitted tirzepatide literature, separate literature on its additives, a Gallup survey, and retrospective cohort studies. NAD found the fit poor on every count.
The tirzepatide literature largely concerned Lilly's FDA-approved products, and nothing in the record bridged ingredient-level evidence to Tirzepatide+ as a finished compound. Neither the survey nor the cohort studies examined Tirzepatide+ at all. There was no evidence on the safety of combining tirzepatide with the additives.
NAD also rejected a defense common in the compounding market — that the FDA's decision to permit compounding during drug shortages substantiated the claims. Permission to compound is not evidence of efficacy.
On personalization, NAD found the ads overstated the process: a prescriber may choose among formulations and adjust a plan, but the product itself is not individually formulated for that patient.
Good Life permanently discontinued several claims during the inquiry — covering clinical results, benefits, ingredients, safety, and sourcing — and said it disagrees with many aspects of the decision but will comply.
Who Is Affected
Good Life and its patients are the immediate parties, but the reasoning reaches any telehealth platform or compounding pharmacy still advertising a compounded GLP-1 as personalized or equivalent to the approved drug. For researchers comparing compounded and approved tirzepatide, it draws a hard line between ingredient data and product data.
Timeline
- April 2025 — Lilly sues compounders including Strive and Empower, then a wave of telehealth sellers, over compounded tirzepatide marketing.
- January 14, 2026 — Strive files an antitrust suit accusing Lilly and Novo Nordisk of suppressing compounded competition.
- May 2026 — Lilly prevails in a separate advertising challenge against Noom over GLP-1 dosing claims.
- November 4, 2026 — NAD issues its Good Life decision.
What This Means for Researchers
The lesson is evidentiary: a claim about a finished compounded product needs product-level data — identity, purity, the specific combination, stability of that combination. Trial results from an approved drug with the same active ingredient do not transfer.
Expect the NAD route to expand — faster and cheaper than litigation, with public decisions and escalation to the Federal Trade Commission for non-compliance.
How to Verify Your Peptides
Before relying on any supplier's marketing, ask for documentation that matches the actual product:
Safe Alternatives
For approved-product context, see our reference pages on tirzepatide and semaglutide. If you are evaluating vendors, the vendor directory lists suppliers with published third-party testing, including Virtus Peptides and Kohan.
Sources
- BBB National Programs, National Advertising Division decision announcement, November 4, 2026
- Regulatory announcements and industry reports on GLP-1 compounding enforcement, 2025–2026